Welcome to our dedicated page for Mereo BioPharma Group news (Ticker: MREO), a resource for investors and traders seeking the latest updates and insights on Mereo BioPharma Group stock.
Mereo BioPharma Group plc reports clinical, partnering, and financial developments for a rare-disease biopharmaceutical pipeline traded in the U.S. through ADSs under MREO. Its recurring updates center on setrusumab (UX143) for osteogenesis imperfecta, alvelestat for alpha-1 antitrypsin deficiency-associated lung disease, and vantictumab for autosomal dominant osteopetrosis type 2.
Company news also covers trial results and data analyses from the ORBIT and COSMIC studies, orphan and Fast Track regulatory designations for alvelestat, cash runway and operating-expense updates, and collaboration activity involving Ultragenyx, āshibio, and other development partners. Reports link program progress with capital allocation across core and non-core rare-disease assets.
Mereo BioPharma (NASDAQ:MREO) reported second quarter 2026 results and corporate updates. The company entered an option and license agreement with Sentynl Therapeutics for alvelestat in AATD‑LD, under which it would be eligible, upon option exercise, to receive $40 million in upfront and R&D payments, up to $435 million in milestones and double‑digit tiered U.S. royalties, while retaining rest‑of‑world commercial rights and leading a funded global Phase 3 trial potentially starting in early 2027.
With partner Ultragenyx, Mereo is in regulatory discussions in the U.S. and U.K. on the path forward for setrusumab in osteogenesis imperfecta after Phase 3 studies that did not meet primary fracture endpoints but showed statistically significant gains in bone mineral density and other measures. Q2 2026 R&D expenses fell to $1.8 million from $5.4 million, G&A to $5.2 million from $5.5 million, and net loss narrowed to $7.0 million from $14.6 million. Cash and cash equivalents were $30.1 million, expected to fund operations into late‑2027. Total assets were $34.7 million and shareholders’ equity $28.7 million at June 30, 2026.
Mereo BioPharma (Nasdaq: MREO) has entered into an option and license agreement granting Sentynl Therapeutics exclusive rights to commercialize alvelestat for alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD) in the U.S., and global manufacturing rights, while Mereo retains commercial rights for the rest of the world.
Mereo will receive a non-refundable option fee and, upon option exercise, is eligible for $40 million in upfront and R&D payments, up to $435 million in regulatory and commercial milestones, and double-digit tiered royalties on U.S. net sales. Sentynl would fund the Phase 3 program on option exercise. Mereo will lead the global Phase 3 study and regulatory interactions, with both companies collaborating during a short option period to refine the Phase 3 design and advance manufacturing. Phase 3 could be initiated in early 2027. Alvelestat, a novel oral neutrophil elastase inhibitor, has Orphan Drug Designation in the U.S. and EU and Fast Track designation from the FDA.
Mereo BioPharma (NASDAQ:MREO) reported first quarter 2026 results and rare disease pipeline updates. Net loss was $6.7 million versus $12.9 million a year earlier, with cash of $36.2 million and runway expected into mid‑2027.
Phase 3 setrusumab studies in osteogenesis imperfecta did not meet primary fracture endpoints but showed statistically significant gains in bone mineral density and vertebral fracture reductions. Mereo is engaging regulators on a pediatric path. Alvelestat Phase 3 is planned as a single ~220‑patient trial pending partnership, and vantictumab is slated to enter Phase 2 in ADO2 in 2H 2026 via partner āshibio.
Mereo (NASDAQ: MREO) reported full‑year 2025 results and clinical updates on March 19, 2026. Cash was $41.0 million as of December 31, 2025, with a stated runway into mid‑2027.
Phase 3 Orbit and Cosmic studies of setrusumab missed primary fracture endpoints but showed statistically significant BMD gains, reductions in vertebral fractures and improved pediatric PROs. Alvelestat Phase 3 planning completed site feasibility (≈220 patients). Vantictumab was outlicensed with a partner planning a Phase 2 in H2 2026.
Mereo BioPharma (NASDAQ: MREO) reported Phase 3 updates for setrusumab (UX143) in osteogenesis imperfecta and progress on alvelestat (MPH-966) for AATD-LD, plus revised cash guidance. As of Dec 31, 2025, cash and equivalents were approximately $41 million, expected to fund operations to mid-2027. Orbit and Cosmic Phase 3 studies did not meet their primary fracture reduction endpoints, but both achieved statistically significant improvements in bone mineral density as a key secondary endpoint. Further analyses and potential regulator interactions are ongoing. Alvelestat Phase 3 is planned as a single global trial (~220 patients, 18 months), and vantictumab was out-licensed with a Phase 2 start planned in 2H 2026.
Mereo BioPharma (NASDAQ: MREO) announced Phase 3 results for setrusumab (UX143) in Osteogenesis Imperfecta on Dec 29, 2025. Both Phase 3 studies, ORBIT and COSMIC, failed to meet their primary endpoint of reducing annualized clinical fracture rate versus placebo or bisphosphonates. Both studies did achieve their secondary endpoints: statistically significant improvements in bone mineral density (BMD). No change in the safety profile was observed. The company reported a $48.7M cash balance at end-Q3 2025 and announced immediate reductions in pre-commercial and manufacturing activities while pursuing further data analyses and partnering for alvelestat.
Mereo (NASDAQ: MREO) reported Q3 2025 results and corporate highlights on Nov 10, 2025. Key near-term catalysts include Phase 3 Orbit and Cosmic setrusumab readouts expected around the end of 2025 (Orbit final analysis threshold p<0.039; Cosmic p<0.05).
Financials: cash $48.7M as of Sep 30, 2025, expected to fund operations into 2027; Q3 R&D expense rose to $4.3M (vs $3.2M prior year); G&A was $6.0M; net loss was $7.0M in Q3 2025.
Corporate items: ongoing alvelestat partnering discussions, retained European commercial rights for vantictumab, and continued pre-commercial work in Europe for setrusumab.
āshibio has entered into an exclusive licensing agreement with Mereo BioPharma (NASDAQ: MREO) for vantictumab, targeting the treatment of autosomal dominant osteopetrosis type 2 (ADO2), a rare bone disorder affecting 1 in 20,000 births.
Vantictumab, a monoclonal antibody that inhibits Wnt signaling pathways by binding to frizzled receptors, has shown promising safety and biomarker data in previous oncology trials. The drug will be developed for ADO2, a genetic disorder caused by CLCN7 gene mutation that results in dense, brittle bones and various complications.
Under the agreement, āshibio gains development and commercialization rights globally, except in Europe, where Mereo retains commercial rights. Preclinical data will be presented at the ASBMR annual meeting in September 2025.
Mereo BioPharma (NASDAQ: MREO) has reported its Q2 2025 financial results and provided corporate updates. The company maintains a strong financial position with $56.1 million in cash as of June 30, 2025, expected to fund operations into 2027. Key highlights include the progression of two Phase 3 studies for setrusumab in osteogenesis imperfecta, with final analyses expected around year-end 2025.
Financial results show R&D expenses increased to $5.4 million in Q2 2025 from $4.9 million in Q2 2024, while G&A expenses decreased to $5.5 million from $7.9 million. The company reported a net loss of $14.6 million for Q2 2025, compared to $12.3 million in Q2 2024. The Orbit study's Data Monitoring Committee confirmed setrusumab's acceptable safety profile, allowing the study to proceed to final analysis.